MabVax Therapeutics sublicenses therapeutics for patented neuroblastoma vaccine

3 July 2018
2019_biotech_test_vial_discovery_big

US clinical-stage oncology drug developer MabVax Therapeutics (OTCQB: TELK) has granted to Denmark-based Y-mAbs Therapeutics an exclusive sublicense to a bi-valent ganglioside based vaccine intended to treat neuroblastoma, a rare pediatric cancer.

News of the deal sent the US firm’s shares up 7.6 to $0.58 by mid-morning trading today.

A third of neuroblastoma patients are diagnosed as infants; and 90% are younger than five years of age at time of diagnosis. Neuroblastoma is responsible for 12% of all cancer deaths in children less than 15 years of age.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology